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Abstract
AIM: To assess the appropriateness of the indication 
and route of administration of proton-pump-inhibitors 
(PPIs) and their associated cost impact. 
METHODS: Data collection was performed prospec-
tively during a 6-mo period on 340 patients who re-
ceived omeprazole intravenously during their hospital 
stay in non-intensive care floors. Updated guidelines 
were used to assess the appropriateness of the indica-
tion and route of administration. 
RESULTS: Complete data collection was available for 
286 patients which were used to assess intravenous 
(IV) PPIs utilization. Around 88% of patients were 
receiving PPIs for claimed stress ulcer prophylaxis 
(SUP) indication; of which, only 17% met the guideline 
criteria for SUP indication, 14% met the criteria for 
non-steroidal-anti-inflammatory drugs-induced ulcer 
prophylaxis, while the remaining 69% were identified 
as having an unjustified indication for PPI use. The 
initiation of IV PPIs was appropriate in 55% of pa-
tients. Half of these patients were candidates for 
switching to the oral dosage form during their hos-
pitalization, while only 36.7% of these patients were 
actually switched. The inappropriate initiation of PPIs 
via  the IV route was more likely to take place on the 
medical floor than the surgical floor (53% vs  36%, P 
= 0.003). The cost analysis associated with the appro-
priateness of the indication for PPI use as well as the 
route of administration of PPI revealed a possible sav-
ing of up to $17 732.5 and $14 571, respectively. 
CONCLUSION: This study highlights the over-utili-
zation of IV PPIs in non-intensive care unit patients. 
Restriction of IV PPI use for justified indications and 
route of administration is recommended.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Proton-pump-inhibitors (PPIs) are the most effective 
agents for reducing gastric acid secretion and are com-
monly used in a variety of  gastrointestinal (GI) related 
disorders[1]. The dramatic increase in PPI prescribing 
patterns over the past several years has raised concerns 
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relating to their appropriate utilization and associated 
cost[2,3]. Many health care centers have raised concerns 
related to the inappropriate use of  the intravenous (IV) 
route of  administration and unsuitable indications and 
to a lesser extent incorrect doses and length of  therapy. 
Furthermore, many patients are being inappropriately 
discharged on PPIs which could potentially increase 
treatment costs, and the risk of  pneumonia and Clostridi-
um difficile associated disease[4]. Part of  the over-utilization 
of  IV PPIs can be explained by their safety profile and 
the tendency of  physicians to manage ill in-patients ag-
gressively[5]. Approved indications for IV PPIs are limited 
to erosive esophagitis in patients unable to tolerate oral 
medications and patients with pathologic hypersecretory 
state including Zollinger-Ellison syndrome[6]. Oral PPIs 
are associated with several advantages compared to the 
IV formulation including lower cost, reduced utilization 
of  hospital resources, and fewer IV related complications. 
Guda et al[6] in 2004 reporting on the use of  IV PPIs in 
two hospital settings observed that 56% of  patients re-
ceiving IV PPIs had inappropriate indications and the 
majority of  these claimed to have stress ulcer prophylaxis 
(SUP) indications. Prophylaxis against stress ulcer is not 
routinely recommended in general medicine patients[4]. 
Inappropriate dosing of  IV PPIs has attributed to a 
292% increase in the cost related to these medications 
and hence has resulted in an additional expenditure of  
$7766 for 64 patients[7]. There is a need to assess the pre-
scribing pattern of  IV PPIs in the Middle East and Arab 
countries. In response to the inadequate literature avail-
able in the aforementioned region, a drug use evaluation 
was conducted to assess the appropriateness of  the indi-
cation and route of  administration of  PPIs and their as-
sociated cost impact in a university hospital in Lebanon.
MATERIALS AND METHODS
Data collection was performed prospectively from 
October 15, 2008 to April 15, 2009 on 340 adult patients 
who received a PPI after being admitted to the medical 
or surgical floors of  a 200 beds university hospital in the 
Beirut area that attracts patients from all over the coun-
try. Patients were identified from the pharmacy computer 
system prior to and during the dispensing process. Data 
collection forms were filled for 340 patients, out of  which 
286 were determined to be complete and accurate. The 
form included data on patient demographics, medical 
problems, list of  medications used, pertinent laboratory 
data, and criteria for PPI IV indication, dose, frequency, 
duration, and indication for switching to oral formula-
tion. Assessment of  the appropriateness of  IV PPI use 
was then performed based on the American Society of  
Health-System Pharmacists guidelines[8] and the Eastern 
Association for the Surgery of  Trauma for SUP[9], non-
steroidal-anti-inflammatory drugs (NSAIDs)-induced ul-
cer prophylaxis[10], and criteria for IV to po conversion[11]. 
Patients assessed for PPI indication were divided into 
two groups, one group of  patients using the drug for 
treatment indication and another group using the drug 
for claimed SUP indication. The claimed SUP indication 
group was then sub-classified into (1) meeting criteria for 
SUP indication; (2) meeting criteria for NSAIDs-induced 
ulcer prophylaxis; and (3) unjustified prophylactic use. 
Another analysis, focusing on the route of  adminis-
tration, divided patients into two groups, one group rep-
resenting those with appropriate initial IV use and the 
other group representing inappropriate initial IV use.
Cost analysis was performed comparing the cost as-
sociated with appropriate initial IV PPI with that of  inap-
propriate initial IV PPI use. The cost included 100 mL 
solution bag, 5 mL syringe, drug vial, IV line and related 
materials. Cost analysis was performed on the unneces-
sary duration of  IV use, in cases where oral PPI was used 
instead of  IV and inappropriate utilization. It was as-
sumed that switching from IV to PO was done 1 d earlier 
in the group of  appropriate IV users and prior to initial 
dispensing in the group of  inappropriate IV users. 
Statistical analysis
Statistical analysis was performed using SPSS software. 
Data were entered into the computer and frequencies, 
percentages, means, and standard deviations were calcu-
lated. Differences in percentages were assessed using the 
χ2 test, and differences in means were assessed using the 
student t test. P-values were assessed at the 5% level. 
RESULTS
Patient characteristics
The study included a similar number of  males and fe-
males. Half  of  the patients were 65 years or older, and 
most of  them were receiving omeprazole 40 mg IV once 
daily. The number of  patients from the medical floor 
and the surgical floor was equal (Table 1).
The reasons for hospital admission were various and 
included surgery, pain, infection, cancer treatment, dys-
pnea, trauma or fracture. 
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Table 1  Patient characteristics (n  = 286)
n  (%)
Age, yr (median ± IQR) 64 ± 30
Weight, kg (median ± IQR) 72 ± 23
Creatinine clearance, mL/min (median ± IQR) 71.5 ± 57.6
Age ≥ 65 yr 143 (51)
Male 149 (52)
Medical floor 146 (51)
Surgical floor 140 (49)
Dose 40 mg omeprazole 272 (95)
Frequency as once daily 251 (88)
Medications
   Heparins 133 (47)
   NSAIDs   74 (26)
   Corticosteroids   74 (26)
   Aspirin (100 mg)   42 (15)
   Clopidogrel 15 (5)
   Acenocoumarol 10 (4)
IQR: Interquartile range; NSAIDs: Non-steroidal-anti-inflammatory 
drugs.
The most common criteria for using the IV route of  
administration were an order for nothing by mouth 
(n = 95, 33.2%), unable to swallow (n = 18, 6.3%), severe 
nausea and vomiting (n = 17, 5.9%), acute GI bleeding 
(n = 12, 4.2%), and others (n = 15, 5.2%) such as gastric 
obstruction, ileus, severe diarrhea, and malabsorption. 
Many patients were on antithrombotics, NSAIDs and 
corticosteroids during hospitalization (Table 1). Other 
medications included antibiotics (n = 205, 71.7%), anal-
gesics (n = 171, 59%), metoclopramide (n = 98, 34.3%), 
antihypertensive drugs (n = 101, 35.3%) and insulin (n = 
32, 11.2%).
Justification of PPI use
The use of  IV PPIs was assessed in 286 patients. The 
indication for claimed SUP was used in 88% of  patients, 
of  which only 17% met the guideline criteria for SUP 
indication, 14% met the criteria for NSAIDs-induced ul-
cer prophylaxis while the majority (69%) were receiving 
PPI for an unjustified indication. These indications for 
PPI treatment were peptic ulcer (4.5%), GERD (1.4%), 
and stress ulcer treatment (2.4%). Stratification of  the 
unjustified prophylactic use was correlated with age ≥ 
65 years and whether or not the patient was receiving 
antithrombotics or corticosteroid therapy (Table 2). An-
tithrombotics mainly consisted of  low molecular-weight 
heparins.
Appropriateness of initial iv use and eligibility for oral 
conversion
Only about 50% of  patients who were initiated on PPIs 
via the IV route were deemed appropriate, of  which half  
were candidates for switching to the oral form during 
their hospitalization. Only one third of  the latter were 
switched to the oral form. The inappropriate initiation 
of  PPIs via the IV route was more likely to take place on 
the medical floor compared with the surgical floor (53% 
vs 36%, P = 0.003).
Regardless of  the type of  indication, the rate of  inap-
propriate initiation of  PPIs via the IV route was similar 
to the rate of  appropriate initiation (P = 0.556). The 
likelihood of  switching patients to the oral form was in-
dependent of  the appropriateness of  initial IV use (36.7% 
vs 38.3%, P = 0.785) (Table 3). Most patients received a 
40 mg IV dose once daily for a period of  approximately 
5 d.
Cost analysis
The cost analysis was based on the mean of  5-d of  IV 
administration which could be avoided in the group with 
inappropriate IV use, and the assumption that switching 
could be done at least 1 d earlier in the group with ap-
propriate IV use.
If  PPIs were used for the appropriate indication and 
by the correct route of  administration in the 286 patients 
assessed during the 6-mo period, at least $17 732.5 and 
$13 183, could have been saved, respectively (Table 4).
DISCUSSION
The high prescribing pattern of  IV PPIs has been dem-
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Table 2  Justification of PPI indications
n  (%)
Out of the total sample (n = 286)
   Treatment indications   35 (12)
   Claimed as using PPI for SUP indication 251 (88)
Classification  of patients claimed as using PPI for SUP 
indication (n = 251)
   Meeting criteria for SUP indication   43 (17)
   Meeting criteria for NSAIDs-induced prophylaxis   35 (14)
      Age ≥ 65 yr + NSAIDs 12 (5)
      NSAIDS + antithrombotics 23 (9)
      NSAIDS + corticosteroids 17 (7)
   Unjustified prophylactic use 173 (69)
      Age ≥ 65 yr   81 (32) 
      Age ≥ 65 yr + LMWH   55 (22)
      Age ≥ 65 yr +  antiplatelets   60 (24)
      Age ≥ 65 yr + corticosteroids   25 (10)
      Others   90 (36)
PPI: Proton-pump-inhibitor; SUP: Stress ulcer prophylaxis.
Table 3  Correlation of initial IV administration with indication 
and eligibility for oral conversion  n (%)
Appropriate 
initial IV use
Inappropriate 
initial IV use
P  value
Total IV use (n = 286) 158 (55) 128 (45)
   Switched   58 (37)   49 (38)    0.785
   Candidate for Switch   82 (52) 127 (99) < 0.001
Indication
   Treatment (35)   22 (14)   13 (10)    0.556
   SUP justified (43)   26 (17)   17 (13)    0.556
   NSAIDs-induced (justified) 
   (35)
  17 (11)   18 (14)    0.556
   Other unjustified prophylaxis 
   (173)
  93 (59)   80 (63)    0.556
   Frequency as once daily 138 (87) 113 (88)  0.81
   Dose 40 mg 152 (96) 120 (95)    0.491
   Medical floor   68 (47)   78 (53)    0.003
   Surgical floor   90 (64)   50 (36)    0.003
   Duration of IV use 
   (median ± IQR)
4.0 ± 4.0 4.0 ± 4.0    0.422
IV: Intravenous.
Table 4  Cost analysis for inappropriate route of administration 
and indication
Appropriate 
initial IV PPI use
Inappropriate 
initial IV PPI use
Candidate for switch n = 82 n = 128
Cost of 40 mg IV PPI daily 
dose that could be avoided 
  $1681 $13 120
Cost of 40 mg PPI oral daily 
dose (if used instead of IV)
    $184    $1434
Cost that could be avoided 
with the oral use
  $1497 $11 686
Total cost that could be avoided 
with IV to po conversion
$13 183
Cost that could be avoided from   $17 732.5
Unjustified prophylactic use 
of IV PPI (n = 173)
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onstrated in this study. The majority of  patients were 
identified as using IV PPIs for claimed SUP indication 
with a relatively small percentage of  patients (17%) meet-
ing the criteria for SUP, which is expected since only 
non-intensive care unit (ICU) patients were included in 
the trial. The inappropriateness of  use was encountered 
more on the medical floor compared with the surgical 
floor. This highlights the need for a clinical pharmacist in 
that area. Among other patients claimed to be treated for 
SUP, 14% met the criteria for other indications such as 
prophylaxis of  NSAIDs-induced ulcer. This left a large 
number of  patients using PPIs for unjustified indica-
tions. Thus, to minimize over-utilization of  PPIs for SUP, 
prescribers should specify the indication and the reason 
for the PPI on the medication orders, which would then 
facilitate medical order screening by the dispensing phar-
macist. Around 36% of  the patients who claimed to re-
ceive IV PPIs for SUP had no risk factors or any known 
justification for PPI use. It seems that age ≥ 65 years 
old was used as a criterion for PPI use; however, these 
patients had several medical illnesses and were on mul-
tiple drug regimens that may have increased the risk of  
adverse effects. A retrospective review of  the medical 
charts of  elderly patients revealed that around 30% of  
geriatric patients with a prescription for a PPI from a ge-
riatric ambulatory care practice within an urban academic 
medical center had no documented indication[12].
These findings highlight the role of  the clinical phar-
macist in the selection of  appropriate candidates for 
switching. 
The cost burden associated with inappropriate IV 
PPI use should be minimized. An annual projection of  
cost could reflect a saving of  $26 366 and $35 465 with 
the appropriate route of  administration and indication, 
respectively. It is important to note that this cost saving 
was underestimated since the cost of  health care staff  
time was not included in the calculations and the delay in 
switching was assumed to be only 1 d. This highlighted 
the crucial role of  a clinical pharmacist to review orders 
for proper indications, route of  administration, and ap-
propriate timing for switching. 
The results of  this study are comparable with several 
trials in the USA and UK that discussed the inappropri-
ate use of  IV PPIs in several institutions[7,13-15]. SUP was 
the most commonly encountered claimed indication for 
IV PPIs. A 14-mo observational study assessing the use 
of  IV PPIs in non-ICU patients revealed that 22% of  
patients were receiving the drug according to their estab-
lished indications. SUP was the presumed indication in 
70% of  patients receiving IV PPIs, of  which only 13% 
were considered appropriate[7]. These findings were also 
supported by Qadeer et al[16] who addressed the concern 
of  SUP in non-ICU patients, stating that such an inter-
vention is often unnecessary and not recommended. 
With regard to the limitations of  this study, the study 
was observational and conducted in a single academic 
medical center. In addition, there are no current estab-
lished guidelines for the appropriate use of  IV PPIs in 
the hospital to evaluate their actual use. Moreover, we as-
sumed that patients with no clear documented indication 
for PPI use received the drug for SUP. An additional 
step could have been to investigate the seniority and/or 
the specialty of  the physicians over-prescribing IV PPIs.
As for the strengths of  this study, the number of  pa-
tients involved was adequate (n = 286) over a sufficient 
period of  time (6 mo). Non-ICU adult patients were 
selected because these patients may be more prone to in-
appropriate SUP treatment. Patients were monitored and 
followed during their hospital stay until discharge, PPI 
discontinuation or switching to oral PPI. In addition, 
there are limited data on the utilization pattern of  an IV 
PPI in an institutional setting.
This study highlights the over-utilization of  PPIs via 
the IV route of  administration and for a claimed SUP in-
dication in non-ICU patients, which results in increased 
cost to the patients, institution and payers. 
Improving the prescribing patterns requires the Hos-
pital Pharmacy and Therapeutics Committee to establish 
guidelines with input from gastroenterologists on the 
proper indications for IV PPIs, criteria for switching, 
dosing, and duration of  therapy. Implementation of  
these guidelines requires multidisciplinary involvement 
and education of  health care professionals concerning 
appropriate use of  this class of  medication. Other ap-
proaches include creating an IV order template, phar-
macists reviewing orders before dispensing to patients, 
and automatic switching to an H2 blocker if  a PPI was 
ordered for SUP until more robust trials on PPI become 
available[17,18].
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COMMENTS
Background
Proton pump inhibitors (PPIs) are the most effective agents for treating acid 
related gastrointestinal (GI) disorders. The utilization of intravenous (IV) 
formulations of PPIs has dramatically increased in health care institutions 
for inappropriate indications, route of administration and length of treatment. 
This is associated with an increased cost burden, increased risk of IV related 
infections, and utilization of hospital resources. 
Research frontiers
Utilization of IV PPIs in a hospital setting in a Middle East country was 
evaluated and compared to data from European and USA hospitals. The 
evaluation was carried out in non-intensive care units where patients do not 
meet the indication and/or route of administration criteria for IV PPIs, especially 
those receiving the drug for stress ulcer prophylaxis (SUP) where little or no 
evidence supports their use.
Innovations and breakthroughs
Reports of the over-utilization of IV PPIs have been published in different 
international journals mainly involving European and American hospital settings. 
Available literature from the Middle East (especially prospective in nature) 
addressing this overuse pattern in non-intensive care units and emphasizing the 
role of a clinical and hospital pharmacist in health care systems is inadequate. 
In addition, a detailed cost analysis projection was performed for inappropriate 
indications and route of administration of PPIs. 
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Applications
The study highlights the essential role of the clinical pharmacist in defining 
candidates for IV PPIs, especially for SUP, and fosters the role of the Pharmacy 
and Therapeutics Committee in implementing restriction guidelines for IV 
PPIs in patients who are not candidates for oral treatment or when the IV 
route shows better efficacy. A multifaceted approach is needed to improve the 
prescribing pattern which would involve education of health care professions 
regarding the appropriate prescribing pattern of IV PPIs.
Terminology
Proton pump inhibitors are the most effective anti-secretory agents which inhibit 
the final step in gastric acid secretion and are used to treat several GI related 
disorders. Stress ulcers also called stress mucosal related disease is a form of 
hemorrhagic gastritis that occurs in patients after major stressful events such 
as trauma, surgery, or severe head injury.
Peer review
The paper is well written. The observations are comparable to those made in 
Europe, USA, and Asia, as acknowledged by the authors in Discussion. The 
appropriateness of the statistics applied to analyze the data obtained may be 
debated, but the use of non-parametric tests is considered preferable in this 
type of studies.
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